Zehentmayr, F; Feurstein, P; Ruznic, E; Langer, B; Grambozov, B; Klebermass, M; Purevdorj, A; Gruber, G; Minasch, D; Heilmann, M; Breitfelder, B; Steffal, C; Gastinger-Grass, G; Kirchhammer, K; Kazil, M; Stranzl, H; Dieckmann, K.
Durvalumab prolongs overall survival whereas radiation dose escalation >66 Gy improves long-term local control in unresectable NSCLC stage III: Updated analysis of the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
J THORAC ONCOL. 2025; 20(3):
Web of Science